Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632874 | 0.87 | — | — | |
| Sulfuric Acid SCHEMBL8008480 | 0.84 | CA2 (0.60) | CA2TSHRTDP1 | |
| Trimethylammonium SCHEMBL9413607 | 0.79 | CA2 (0.53) | CA2TSHRTDP1 | |
| Trimethylammonium SCHEMBL2157043 | 0.77 | CA2 (0.50) | CA2TSHRTDP1 | |
| Dioxane SCHEMBL6720843 | 0.72 | CA2 (0.45) | CA2 | |
| Trimethylammonium SCHEMBL28866078 | 0.71 | CA2 (0.41) | CA2TSHRTDP1 | |
| Trimethylammonium SCHEMBL10696615 | 0.71 | CA2 (0.41) | CA2TSHRTDP1 | |
| Trimethylammonium SCHEMBL2916235 | 0.71 | CA2 (0.41) | CA2TSHRTDP1 | |
| Trimethylammonium SCHEMBL140641 | 0.71 | CA2 (0.41) | CA2TSHRTDP1 | |
| SCHEMBL7217 | 0.69 | CA2 (1.00) | CA2TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654288-B9 | POLYSACCHARIDES DERIVATIVES WITH HIGH ANTITHROMBOTIC ACTIVITY IN PLASMA | INALCO SPA (IT) | 2010-06-23 | — | — | EP | disclosed |
| US-7687249-B2 | Polysaccharide derivatives with high antithrombotic activity in plasma | INALCO S.P.A. (IT) | 2010-03-30 | — | — | US | disclosed |
| EP-1654288-B1 | POLYSACCHARIDES DERIVATIVES WITH HIGH ANTITHROMBOTIC ACTIVITY IN PLASMA | INALCO SPA (IT) | 2010-02-17 | — | — | EP | disclosed |
| US-20090264402-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20070042993-A1 | Polysaccharides derivatives with high antithrombotic activity in plasma | INALCO S.P.A. (IT) | 2007-02-22 | — | — | US | disclosed |
| US-20060281152-A1 | Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation | ZOPPETTI GIORGIO | 2006-12-14 | — | — | US | disclosed |
| EP-1654288-A1 | POLYSACCHARIDES DERIVATIVES WITH HIGH ANTITHROMBOTIC ACTIVITY IN PLASMA | Inalco S.p.A. (IT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014656-A1 | POLYSACCHARIDES DERIVATIVES WITH HIGH ANTITHROMBOTIC ACTIVITY IN PLASMA | INALCO S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| US-20040146994-A1 | Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation | INALCO S.P.A. (IT) | 2004-07-29 | — | — | US | disclosed |
| EP-1268559-A1 | GLYCOSAMINOGLYCANS DERIVED FROM THE K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITY AND PROCESS FOR THEIR PREPARATION | INALCO SpA (IT) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072848-A1 | GLYCOSAMINOGLYCANS DERIVED FROM THE K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITY AND PROCESS FOR THEIR PREPARATION | INALCO S.P.A. (IT) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042993-A1 | Polysaccharides derivatives with high antithrombotic activity in plasma | PIGS, PROC, ENGASE | CA2 3595/4885TSHR 3768/4885TDP1 4549/4885 |
| US-20090264402-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | DPP7, SCN5A, DCTN1 | CA2 1558/4885TSHR 4289/4885TDP1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.